| Literature DB >> 33909313 |
Silas A Buck1,2, Thomas Steinkellner3,4, Despoina Aslanoglou2, Michael Villeneuve2, Sai H Bhatte2, Victoria C Childers2, Sophie A Rubin2, Briana R De Miranda5, Emma I O'Leary1, Elizabeth G Neureiter1,2, Keri J Fogle6,7, Michael J Palladino6,7, Ryan W Logan8,9, Jill R Glausier2, Kenneth N Fish2, David A Lewis2, J Timothy Greenamyre5,7,10, Brian D McCabe11, Claire E J Cheetham12, Thomas S Hnasko3,13, Zachary Freyberg2,14.
Abstract
Age is the greatest risk factor for Parkinson's disease (PD) which causes progressive loss of dopamine (DA) neurons, with males at greater risk than females. Intriguingly, some DA neurons are more resilient to degeneration than others. Increasing evidence suggests that vesicular glutamate transporter (VGLUT) expression in DA neurons plays a role in this selective vulnerability. We investigated the role of DA neuron VGLUT in sex- and age-related differences in DA neuron vulnerability using the genetically tractable Drosophila model. We found sex differences in age-related DA neurodegeneration and its associated locomotor behavior, where males exhibit significantly greater decreases in both DA neuron number and locomotion during aging compared with females. We discovered that dynamic changes in DA neuron VGLUT expression mediate these age- and sex-related differences, as a potential compensatory mechanism for diminished DA neurotransmission during aging. Importantly, female Drosophila possess higher levels of VGLUT expression in DA neurons compared with males, and this finding is conserved across flies, rodents, and humans. Moreover, we showed that diminishing VGLUT expression in DA neurons eliminates females' greater resilience to DA neuron loss across aging. This offers a new mechanism for sex differences in selective DA neuron vulnerability to age-related DA neurodegeneration. Finally, in mice, we showed that the ability of DA neurons to achieve optimal control over VGLUT expression is essential for DA neuron survival. These findings lay the groundwork for the manipulation of DA neuron VGLUT expression as a novel therapeutic strategy to boost DA neuron resilience to age- and PD-related neurodegeneration.Entities:
Keywords: zzm321990Drosophilazzm321990; aging; dopamine; neurodegeneration; vesicular glutamate transporter
Mesh:
Substances:
Year: 2021 PMID: 33909313 PMCID: PMC8135008 DOI: 10.1111/acel.13365
Source DB: PubMed Journal: Aging Cell ISSN: 1474-9718 Impact factor: 11.005
FIGURE 1Sex differences in age‐dependent locomotor loss in Drosophila. Adult male flies show progressive loss of 24‐h locomotion across aging compared with females who only show diminished locomotion at day 60 post‐eclosion. Results represented as mean ± SEM; **p < 0.01, ***p < 0.001 compared with opposite sex, ## p < 0.01, #### p < 0.0001 compared with locomotion in 2‐day‐old flies by Bonferroni post hoc comparison; n = 11–31 animals per group
FIGURE 2Intersectional genetic reporter shows altered DA neuron dVGLUT expression in response to vesicular DA depletion and to sex. (a) Representative confocal image demonstrating TH (magenta) and dVGLUT (green) mRNA expression via multiplex RNAscope in neurons of wild‐type w1118 fly central brain 14 days post‐eclosion; scale bar = 25 μm. Inset shows a zoomed‐in cell expressing both TH and dVGLUT mRNA; scale bar = 10 μm. (b) Quantification of the fraction of TH+ neurons that express dVGLUT via RNAscope labeling in adult central brain shows 27 ± 3.7% of TH+ DA neurons are also dVGLUT+ (n = 11 brains). (c) Schematic where an intersectional genetic luciferase reporter of dVGLUT expression is expressed only in DA neurons that express both TH and dVGLUT. (d) Panel i: The TH promoter drives LexA to express B3 recombinase (B3R) in TH+ cells. Panel ii: B3R excises a transcriptional stop cassette within UAS‐Luciferase. Panel iii: This permits successful dVGLUT‐GAL4‐driven transactivation of UAS‐Luciferase selectively in TH+/dVGLUT+ cells. (e) Vesicular DA depletion by reserpine (300 μM, 24 h) significantly upregulates dVGLUT expression in DA neurons compared with vehicle (2.6‐fold increase; t 4 = 3.8, p = 0.020). (f) Amphetamine (10 mM, 24 h) also increases DA neuron dVGLUT expression 1.9‐fold versus vehicle (t 8 = 2.5, p = 0.039). (g) Increasing age progressively increases DA neuron dVGLUT expression (one‐way ANOVA: p < 0.0001) with a 3.5‐fold increase in dVGLUT expression by day 40 versus day 2 post‐eclosion (Bonferroni post hoc test: p = 0.0001). Results represented as mean ± SEM; *p < 0.01 versus vehicle, **p < 0.01, ***p < 0.001 versus Day 2; n = 3–7 homogenates of 5 brains per group in intersectional luciferase reporter studies
FIGURE 3Sex differences in DA neuron VGLUT expression. (a) Using DA neuron dVGLUT luciferase reporter flies, we observed sex differences in DA neuron dVGLUT expression with female flies expressing 2.1‐fold more dVGLUT compared with males at 14 days post‐eclosion (t 5 = 3.4, p = 0.019); n = 3–4 homogenates of five brains per group. (b) In postmortem human VTA/SNc of male and female subjects, representative images of multiplex fluorescent in situ hybridization demonstrate TH (magenta) and VGLUT2 (green) mRNA expression; yellow arrows denote TH+/VGLUT2+ neurons. Whole field image scale bar = 25 μm, inset scale bar = 10 μm. (c) Human TH+/VGLUT2+ neuron density is 6.6 times higher in female subjects compared with males (t 2 = 4.8, p = 0.040); n = 2 subjects per group. (d) Rat TH+ midbrain neurons show 2.4‐fold elevated VGLUT2 protein expression in females versus males via immunohistochemistry (t 18 = 2.4, p = 0.029); n = 6 males, 14 females. Results represented as mean ± SEM; *p < 0.05 by unpaired t test
FIGURE 4dVGLUT RNAi knockdown diminishes sex‐ and region‐selective DA neuron resilience in aging. (a) Representative multiphoton images of GFP‐labeled DA neurons within the SOG of whole Drosophila adult central brain from flies with the following genotypes: TH‐GAL4/UAS‐GFP (Control) (Top Row) versus TH‐GAL4,UAS‐GFP/UAS‐dVGLUT RNAi (dVGLUT RNAi) (Bottom Row); scale bars = 20 μm. (b) Representative multiphoton images of PAL DA neurons; scale bars = 20 μm. (c) Representative multiphoton images of PAM DA neurons; scale bars = 20 μm. (d) Locomotion over a 24‐h period in male and female control and dVGLUT RNAi flies. Results represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with control by Bonferroni post hoc test, # p < 0.05, ## p < 0.01, #### p < 0.0001 compared with day 2 post‐eclosion by Bonferroni post hoc test. n = 3–8 brains per group for neuron counts and n = 24–49 flies for locomotion
FIGURE 5Dopamine (DA) neuron survival in response to different levels of AAV‐mediated VGLUT2 overexpression. (a) Schematic of AAVs used for cell type‐specific VGLUT2 overexpression in SNc DA neurons of DATCre mice. (b, c) Detection of VGLUT2 protein in (b) cell bodies, and (c) striatal terminals of SNc DA neurons after unilateral injection of AAV‐VGLUT2 (left panel), AAV‐VGLUT2‐eGFP concentrated titer (middle panel), and AAV‐VGLUT2‐eGFP original titer (right panel) in DATCre mice. Ipsi indicates ipsilateral site of viral injection; contralateral side is the uninjected control. (d) Quantification of striatal VGLUT2 density relative to uninjected contralateral sites. (e) Representative midbrain (left panel) and striatal sections (right panel) labeled for TH in mice unilaterally injected with either AAV‐VGLUT2 (upper panel), concentrated titer AAV‐VGLUT2‐eGFP (middle panel), or original titer AAV‐VGLUT2‐eGFP (lower panel); scale bars = 500 μm. (f) Left panel: Quantification of TH+ neuron number (left panel) and striatal density of TH+ DA nerve terminals (right panel). Results represented as mean ± SEM; n = 3–4 animals per group. *p < 0.05, ***p < 0.001 compared by Bonferroni post hoc test